Overview

Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

Status:
Completed
Trial end date:
2020-06-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to determine whether fostamatinib is safe and effective in treating patients with persistent/chronic Immune Thrombocytopenic Purpura (ITP) over a 5 year period.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Rigel Pharmaceuticals
Criteria
Inclusion Criteria:

- Completed week 24 evaluation of Study C935788-047 or Study C935788-048 or discontinued
early due to lack of response.

- Able and willing to give written informed consent

Exclusion Criteria:

- Discontinued participation in Study C935788-047 or Study C935788-048 for any reason
other than lack of response

- Poorly controlled hypertension during Study C935788-047 or Study C935788-048

- Significant infection, an acute infection such as influenza, or known inflammatory
process